Redeye ups its near-term sales estimates and adjusts its fair value range for Acarix following steps...
Redeye comments on AVTECH's preliminary numbers for Q4'22 which was largely in line with our estimat...
On January 11, 2023, Brain+ released the findings of a study conducted by Nottingham University as p...
Redeye states that Neonode’s patent 879 is judged not to be unpatentable – implying a crucial win fo...
Based on Nordea card data, the Nordic restaurant market has remained robust in Q4.
Redeye comments on the news released earlier today, Wyld Networks has received a large order for its...
SolidX rapporterade ett starkt andra kvartal för räkenskapsåret 2022/23, trots att perioden delvis p...
Investors House announced yesterday (11 January) that its zoning plan for Neilikkatie 17 in Tikkuril...
Boreo has conducted three acquisitions since its Q3 report, with aggregated net sales of EUR 6m and ...
Q4 results due Friday, 10 February Sales +32% y-o-y on recent order momentum We cut '23e-'24e EBIT b...
Renodlar verksamheten… Candles har meddelat att de avslutar samarbetet med Newell brands gällande di...
Redeye slightly adjusts our expectations on 2023e based on the price adjustments made by CMS in the ...
Redeye ser positivt på nattens besked att BioArctics partner Eisai ansökt om marknadsgodkännande av ...
Q4 report due on Tuesday, 7 February We expect EBIT margin to bottom out at 9.
Ahead of the full-year results, we note that the encouraging trends in the US, which we highlighted ...
Redeye takes a positive stance towards CombinedX's acquisition of the Microsoft-focused CRM speciali...
Fastighetsbolaget inleder förvaltning av egna hyresrätter och framöver är förvärv i fokus.
Redeye updates its outlook on Calliditas, anticipating US launch support and the European launch ove...
STENOCARE announced on Monday, January 9th, that products were delivered to its five markets during ...
Redeye comments on Genovis following today's news regarding a sublicensing of Xork to Astellas Pharm...
